Skip to main content
PMC home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1994 Apr 1;179(4):1343–1347. doi: 10.1084/jem.179.4.1343

Oncostatin M, leukemia inhibitory factor, and interleukin 6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gp130

PMCID: PMC2191439  PMID: 8145046

Abstract

We analyzed the stimulatory effect of oncostatin M (OSM), leukemia inhibitory factor (LIF), interleukin 6 (IL-6), IL-11, and the inhibitory effect of anti-IL-6 antibody (Ab), anti-IL-6 receptor monoclonal antibody (mAb), and anti-gp130 mAb on the growth of human plasmacytoma cells freshly isolated from a patient with multiple myeloma. The purified cells showed a plasmacytoid morphology and expressed CD38, CD54, and CD56 antigens but no CD3, CD5, CD10, CD19, CD20, or very late antigen 5. IL-6 receptor (IL-6R) and its signal transducer, gp130, were expressed on their cell surface at a low level. Dose-dependent proliferation of the cells in response to OSM, LIF, and IL-6, but not to IL-11, was observed using [3H]TdR incorporation in vitro. Both anti-IL-6 Ab and anti-IL-6R mAb inhibited the growth of the cells in the presence or absence of exogenous IL-6. These cells release IL-6 but not OSM or LIF into the culture supernatant during short-term culture. Therefore, an autocrine growth mechanism mediated by IL-6, but not by OSM or LIF, was confirmed. Furthermore, anti-gp130 mAb completely inhibited the proliferation of the cells induced by OSM, LIF, as well as IL-6. These data indicate that OSM, LIF, and IL-6 can act as growth factors of human plasmacytoma cells through a common signal transducer, gp130, on their cell surface, and also suggest the potential therapeutic application of anti-gp130 mAb, as well as anti-IL- 6R mAb against myeloma/plasmacytomas.

Full Text

The Full Text of this article is available as a PDF (528.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Caligaris-Cappio F., Bergui L., Tesio L., Pizzolo G., Malavasi F., Chilosi M., Campana D., van Camp B., Janossy G. Identification of malignant plasma cell precursors in the bone marrow of multiple myeloma. J Clin Invest. 1985 Sep;76(3):1243–1251. doi: 10.1172/JCI112080. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Gearing D. P., Comeau M. R., Friend D. J., Gimpel S. D., Thut C. J., McGourty J., Brasher K. K., King J. A., Gillis S., Mosley B. The IL-6 signal transducer, gp130: an oncostatin M receptor and affinity converter for the LIF receptor. Science. 1992 Mar 13;255(5050):1434–1437. doi: 10.1126/science.1542794. [DOI] [PubMed] [Google Scholar]
  3. Greipp P. R., Raymond N. M., Kyle R. A., O'Fallon W. M. Multiple myeloma: significance of plasmablastic subtype in morphological classification. Blood. 1985 Feb;65(2):305–310. [PubMed] [Google Scholar]
  4. Hibi M., Murakami M., Saito M., Hirano T., Taga T., Kishimoto T. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell. 1990 Dec 21;63(6):1149–1157. doi: 10.1016/0092-8674(90)90411-7. [DOI] [PubMed] [Google Scholar]
  5. Hilton D. J., Gough N. M. Leukemia inhibitory factor: a biological perspective. J Cell Biochem. 1991 May;46(1):21–26. doi: 10.1002/jcb.240460105. [DOI] [PubMed] [Google Scholar]
  6. Hirata Y., Taga T., Hibi M., Nakano N., Hirano T., Kishimoto T. Characterization of IL-6 receptor expression by monoclonal and polyclonal antibodies. J Immunol. 1989 Nov 1;143(9):2900–2906. [PubMed] [Google Scholar]
  7. Iwato K., Kawano M., Asaoku H., Tanabe O., Tanaka H., Kuramoto A. Separation of human myeloma cells from bone marrow aspirates in multiple myeloma and their proliferation and M-protein secretion in vitro. Blood. 1988 Aug;72(2):562–566. [PubMed] [Google Scholar]
  8. Kawano M. M., Huang N., Harada H., Harada Y., Sakai A., Tanaka H., Iwato K., Kuramoto A. Identification of immature and mature myeloma cells in the bone marrow of human myelomas. Blood. 1993 Jul 15;82(2):564–570. [PubMed] [Google Scholar]
  9. Kawano M. M., Huang N., Tanaka H., Ishikawa H., Sakai A., Tanabe O., Nobuyoshi M., Kuramoto A. Homotypic cell aggregations of human myeloma cells with ICAM-1 and LFA-1 molecules. Br J Haematol. 1991 Dec;79(4):583–588. doi: 10.1111/j.1365-2141.1991.tb08085.x. [DOI] [PubMed] [Google Scholar]
  10. Kishimoto T., Akira S., Taga T. Interleukin-6 and its receptor: a paradigm for cytokines. Science. 1992 Oct 23;258(5082):593–597. doi: 10.1126/science.1411569. [DOI] [PubMed] [Google Scholar]
  11. Klein B., Wijdenes J., Zhang X. G., Jourdan M., Boiron J. M., Brochier J., Liautard J., Merlin M., Clement C., Morel-Fournier B. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood. 1991 Sep 1;78(5):1198–1204. [PubMed] [Google Scholar]
  12. Klein B., Zhang X. G., Jourdan M., Content J., Houssiau F., Aarden L., Piechaczyk M., Bataille R. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood. 1989 Feb;73(2):517–526. [PubMed] [Google Scholar]
  13. Kubagawa H., Vogler L. B., Capra J. D., Conrad M. E., Lawton A. R., Cooper M. D. Studies on the clonal origin of multiple myeloma. Use of individually specific (idiotype) antibodies to trace the oncogenic event to its earliest point of expression in B-cell differentiation. J Exp Med. 1979 Oct 1;150(4):792–807. doi: 10.1084/jem.150.4.792. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Liu J., Modrell B., Aruffo A., Marken J. S., Taga T., Yasukawa K., Murakami M., Kishimoto T., Shoyab M. Interleukin-6 signal transducer gp130 mediates oncostatin M signaling. J Biol Chem. 1992 Aug 25;267(24):16763–16766. [PubMed] [Google Scholar]
  15. Lotz M., Moats T., Villiger P. M. Leukemia inhibitory factor is expressed in cartilage and synovium and can contribute to the pathogenesis of arthritis. J Clin Invest. 1992 Sep;90(3):888–896. doi: 10.1172/JCI115964. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Nair B. C., DeVico A. L., Nakamura S., Copeland T. D., Chen Y., Patel A., O'Neil T., Oroszlan S., Gallo R. C., Sarngadharan M. G. Identification of a major growth factor for AIDS-Kaposi's sarcoma cells as oncostatin M. Science. 1992 Mar 13;255(5050):1430–1432. doi: 10.1126/science.1542792. [DOI] [PubMed] [Google Scholar]
  17. Nordan R. P., Potter M. A macrophage-derived factor required by plasmacytomas for survival and proliferation in vitro. Science. 1986 Aug 1;233(4763):566–569. doi: 10.1126/science.3726549. [DOI] [PubMed] [Google Scholar]
  18. Ogata A., Tagoh H., Lee T., Kuritani T., Takahara Y., Shimamura T., Ikegami H., Kurimoto M., Yoshizaki K., Kishimoto T. A new highly sensitive immunoassay for cytokines by dissociation-enhanced lanthanide fluoroimmunoassay (DELFIA). J Immunol Methods. 1992 Apr 8;148(1-2):15–22. doi: 10.1016/0022-1759(92)90153-k. [DOI] [PubMed] [Google Scholar]
  19. Paul S. R., Barut B. A., Bennett F., Cochran M. A., Anderson K. C. Lack of a role of interleukin 11 in the growth of multiple myeloma. Leuk Res. 1992;16(3):247–252. doi: 10.1016/0145-2126(92)90062-c. [DOI] [PubMed] [Google Scholar]
  20. Paul S. R., Bennett F., Calvetti J. A., Kelleher K., Wood C. R., O'Hara R. M., Jr, Leary A. C., Sibley B., Clark S. C., Williams D. A. Molecular cloning of a cDNA encoding interleukin 11, a stromal cell-derived lymphopoietic and hematopoietic cytokine. Proc Natl Acad Sci U S A. 1990 Oct;87(19):7512–7516. doi: 10.1073/pnas.87.19.7512. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Rose T. M., Bruce A. G. Oncostatin M is a member of a cytokine family that includes leukemia-inhibitory factor, granulocyte colony-stimulating factor, and interleukin 6. Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8641–8645. doi: 10.1073/pnas.88.19.8641. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Saito T., Taga T., Miki D., Futatsugi K., Yawata H., Kishimoto T., Yasukawa K. Preparation of monoclonal antibodies against the IL-6 signal transducer, gp130, that can inhibit IL-6-mediated functions. J Immunol Methods. 1993 Aug 9;163(2):217–223. doi: 10.1016/0022-1759(93)90125-q. [DOI] [PubMed] [Google Scholar]
  23. Sato K., Tsuchiya M., Saldanha J., Koishihara Y., Ohsugi Y., Kishimoto T., Bendig M. M. Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res. 1993 Feb 15;53(4):851–856. [PubMed] [Google Scholar]
  24. Stöckli K. A., Lottspeich F., Sendtner M., Masiakowski P., Carroll P., Götz R., Lindholm D., Thoenen H. Molecular cloning, expression and regional distribution of rat ciliary neurotrophic factor. Nature. 1989 Dec 21;342(6252):920–923. doi: 10.1038/342920a0. [DOI] [PubMed] [Google Scholar]
  25. Taga T., Narazaki M., Yasukawa K., Saito T., Miki D., Hamaguchi M., Davis S., Shoyab M., Yancopoulos G. D., Kishimoto T. Functional inhibition of hematopoietic and neurotrophic cytokines by blocking the interleukin 6 signal transducer gp130. Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10998–11001. doi: 10.1073/pnas.89.22.10998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Uchiyama H., Barut B. A., Chauhan D., Cannistra S. A., Anderson K. C. Characterization of adhesion molecules on human myeloma cell lines. Blood. 1992 Nov 1;80(9):2306–2314. [PubMed] [Google Scholar]
  27. Van Damme J., Opdenakker G., Simpson R. J., Rubira M. R., Cayphas S., Vink A., Billiau A., Van Snick J. Identification of the human 26-kD protein, interferon beta 2 (IFN-beta 2), as a B cell hybridoma/plasmacytoma growth factor induced by interleukin 1 and tumor necrosis factor. J Exp Med. 1987 Mar 1;165(3):914–919. doi: 10.1084/jem.165.3.914. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Yang Y. C., Yin T. Interleukin-11 and its receptor. Biofactors. 1992 Dec;4(1):15–21. [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES